Ir-1 Case Study Of Melanoma

Brain metastases melanoma patients have a high mortality rate and a poor prognosis. Clinical studies had shown that the CTLA-4 inhibitor (Ipilimumab) has activity in these patients; however, there are currently limited data on the use of anti-PD-1 therapies. We herein discuss a case of a 62-year-old male diagnosed with melanoma, and then he was received treatment with dacarbazine followed by high-dose interferon. On subsequent follow up he was found to have a brain lesion and many other lesions. Pembrolizumab was management by 2mg/kg every 3 weeks for 6 cycles. The intracranial lesion presented special changes with other lesions became much smaller than before. He experienced immunorelated adverse events (ir-AEs), and then we gave him cortisol